Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zilovertamab vedotin

Phase 3Antibody–drug conjugate

Zilovertamab vedotin is one of 160 biologic programs targeting DLBCL. It is currently in Phase 3.

5

Indications

10

Total Trials

8

Active Trials

159

Competitors

Pipeline

Status by Indication[3][1]

Indication

DLBCLRecruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaRecruiting

Urothelial CarcinomaActive, not recruiting

DLBCLPreclinical

Recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPreclinical

Recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

109 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Rituxan

Oncovin

Polivy

Gemzar

Johnson & Johnson

Adriamycin

Gazyva

Oncovin

Cytoxan

BBaxter Healthcare Corporation

Rayos

RRoxane Laboratories

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

DLBCL

NCT05139017

Q2 2028

Phase 1/2Active, not recruiting

Urothelial Carcinoma

NCT05562830

Q1 2029

PreclinicalRecruiting

B-Cell Acute Lymphoblastic Leukemia

NCT06395103

Q2 2029

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT05406401

Phase 2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT05458297

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma3 trials

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT05406401·60 enrolled

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT05144841·140 enrolled

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06717347·1,046 enrolled

Urothelial Carcinoma1 trial

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT05562830·48 enrolled

Hematologic Malignancies1 trial

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03833180·91 enrolled

Solid Tumors1 trial

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT04504916·102 enrolled

B-cell acute lymphoblastic leukemia1 trial

LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06395103·90 enrolled

3 more indications

DLBCL1 trial

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT05139017·290 enrolled

Lymphoma, Large B-Cell, Diffuse1 trial

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06890884·594 enrolled

Chronic Lymphocytic Leukemia1 trial

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT05458297·189 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Zilovertamab vedotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zilovertamab vedotin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zilovertamab vedotin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Related News